Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/fillip-to-cheaper-hepatitis-c-drug-gs-mudur-4675073/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/fillip-to-cheaper-hepatitis-c-drug-gs-mudur-4675073/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/fillip-to-cheaper-hepatitis-c-drug-gs-mudur-4675073/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/fillip-to-cheaper-hepatitis-c-drug-gs-mudur-4675073/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68030c5f75e61-trace').style.display = (document.getElementById('cakeErr68030c5f75e61-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr68030c5f75e61-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68030c5f75e61-code').style.display = (document.getElementById('cakeErr68030c5f75e61-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr68030c5f75e61-context').style.display = (document.getElementById('cakeErr68030c5f75e61-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr68030c5f75e61-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr68030c5f75e61-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 27028,
		&#039;title&#039; =&gt; &#039;Fillip to cheaper hepatitis C drug -GS Mudur&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;India&#039;s patent regulating agency today rejected a US company&#039;s patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900 (Rs 55,600) for a 12-week course of treatment.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The decision will allow generic drug makers to manufacture their own low-cost versions of the medicine. A research study by scientists at the University of Liverpool, published last year, had calculated that the medicine could be produced for only $101 (Rs 6,240) for the 12-week course of treatment.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;This drug makes hepatitis C treatment more effective. We&#039;re hoping this decision opens the floodgates for more open competition that could rapidly lower the price,&amp;quot; said Manica Balasegaram, executive director with the Medecins Sans Frontieres&#039; (MSF) Access Campaign, a humanitarian initiative to expand access to drugs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sofosbuvir is available in the US for $84,000 (Rs 51.9 lakh) for a course of treatment but Gilead - while awaiting a decision from India&#039;s patent office - had last September announced that it would sell the drug in India at $900.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It had also signed pacts with seven Indian drug companies, allowing them to sell generic versions of the drug at even lower prices. But patients&#039; rights groups believe the drug would remain out of reach of most Indian patients even at those lowered prices.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The MSF Access Campaign plans to expand treatment for hepatitis C in India and eight other developing countries. It has been hoping for inexpensive versions of the medicine that it expects will remain the &amp;quot;backbone of (the) hepatitis C treatment regimen in the coming years&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Currently, treatment for the hepatitis C viral infection involves an injectable product called pegylated interferon with an anti-viral drug called ribavarin.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
But, an MSF official said, the success rate of the pegylated interferon regimen in eliminating the infection is about 70 per cent, while it is over 90 per cent with sofosbuvir.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We know from various manufacturers in India that they could produce this drug in future for as little as $101 for a three-month course of treatment,&amp;quot; said Andrew Hill, a senior research fellow at Liverpool University in the UK.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Hill and his colleagues had last year published a study in the journal Clinical Infectious Diseases in which they had estimated that the manufacturing costs of several &amp;quot;direct-acting&amp;quot; anti-viral drugs, sofosbuvir among them, could range between $100 and $250 for a 12-week treatment course.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The patent examiners denied the patent claim citing Section 3(d) of India&#039;s patent act, which disallows patents on new or tweaked versions of known or old drug molecules. Many health activists regard this clause as a safeguard.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Gilead has the right to move an appeal with the patent authority or approach an Indian court.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 16 January, 2015, http://www.telegraphindia.com/1150116/jsp/nation/story_8708.jsp#.VLiwoHvxyBE&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;fillip-to-cheaper-hepatitis-c-drug-gs-mudur-4675073&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4675073,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 27028,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Fillip to cheaper hepatitis C drug -GS Mudur&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Intellectual Property Rights,IPRs,patent,patents,generic medicine,generic medicines,Hepatitis C&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph


New Delhi: India&#039;s patent regulating agency today rejected a US company&#039;s patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.


The Indian Patents Controller has denied...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;New Delhi: &lt;/em&gt;India&#039;s patent regulating agency today rejected a US company&#039;s patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900 (Rs 55,600) for a 12-week course of treatment.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The decision will allow generic drug makers to manufacture their own low-cost versions of the medicine. A research study by scientists at the University of Liverpool, published last year, had calculated that the medicine could be produced for only $101 (Rs 6,240) for the 12-week course of treatment.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;This drug makes hepatitis C treatment more effective. We&#039;re hoping this decision opens the floodgates for more open competition that could rapidly lower the price,&amp;quot; said Manica Balasegaram, executive director with the Medecins Sans Frontieres&#039; (MSF) Access Campaign, a humanitarian initiative to expand access to drugs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sofosbuvir is available in the US for $84,000 (Rs 51.9 lakh) for a course of treatment but Gilead - while awaiting a decision from India&#039;s patent office - had last September announced that it would sell the drug in India at $900.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It had also signed pacts with seven Indian drug companies, allowing them to sell generic versions of the drug at even lower prices. But patients&#039; rights groups believe the drug would remain out of reach of most Indian patients even at those lowered prices.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The MSF Access Campaign plans to expand treatment for hepatitis C in India and eight other developing countries. It has been hoping for inexpensive versions of the medicine that it expects will remain the &amp;quot;backbone of (the) hepatitis C treatment regimen in the coming years&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Currently, treatment for the hepatitis C viral infection involves an injectable product called pegylated interferon with an anti-viral drug called ribavarin.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;But, an MSF official said, the success rate of the pegylated interferon regimen in eliminating the infection is about 70 per cent, while it is over 90 per cent with sofosbuvir.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We know from various manufacturers in India that they could produce this drug in future for as little as $101 for a three-month course of treatment,&amp;quot; said Andrew Hill, a senior research fellow at Liverpool University in the UK.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Hill and his colleagues had last year published a study in the journal Clinical Infectious Diseases in which they had estimated that the manufacturing costs of several &amp;quot;direct-acting&amp;quot; anti-viral drugs, sofosbuvir among them, could range between $100 and $250 for a 12-week treatment course.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The patent examiners denied the patent claim citing Section 3(d) of India&#039;s patent act, which disallows patents on new or tweaked versions of known or old drug molecules. Many health activists regard this clause as a safeguard.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Gilead has the right to move an appeal with the patent authority or approach an Indian court.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 27028,
	&#039;title&#039; =&gt; &#039;Fillip to cheaper hepatitis C drug -GS Mudur&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;India&#039;s patent regulating agency today rejected a US company&#039;s patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900 (Rs 55,600) for a 12-week course of treatment.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The decision will allow generic drug makers to manufacture their own low-cost versions of the medicine. A research study by scientists at the University of Liverpool, published last year, had calculated that the medicine could be produced for only $101 (Rs 6,240) for the 12-week course of treatment.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;This drug makes hepatitis C treatment more effective. We&#039;re hoping this decision opens the floodgates for more open competition that could rapidly lower the price,&amp;quot; said Manica Balasegaram, executive director with the Medecins Sans Frontieres&#039; (MSF) Access Campaign, a humanitarian initiative to expand access to drugs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sofosbuvir is available in the US for $84,000 (Rs 51.9 lakh) for a course of treatment but Gilead - while awaiting a decision from India&#039;s patent office - had last September announced that it would sell the drug in India at $900.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It had also signed pacts with seven Indian drug companies, allowing them to sell generic versions of the drug at even lower prices. But patients&#039; rights groups believe the drug would remain out of reach of most Indian patients even at those lowered prices.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The MSF Access Campaign plans to expand treatment for hepatitis C in India and eight other developing countries. It has been hoping for inexpensive versions of the medicine that it expects will remain the &amp;quot;backbone of (the) hepatitis C treatment regimen in the coming years&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Currently, treatment for the hepatitis C viral infection involves an injectable product called pegylated interferon with an anti-viral drug called ribavarin.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
But, an MSF official said, the success rate of the pegylated interferon regimen in eliminating the infection is about 70 per cent, while it is over 90 per cent with sofosbuvir.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We know from various manufacturers in India that they could produce this drug in future for as little as $101 for a three-month course of treatment,&amp;quot; said Andrew Hill, a senior research fellow at Liverpool University in the UK.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Hill and his colleagues had last year published a study in the journal Clinical Infectious Diseases in which they had estimated that the manufacturing costs of several &amp;quot;direct-acting&amp;quot; anti-viral drugs, sofosbuvir among them, could range between $100 and $250 for a 12-week treatment course.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The patent examiners denied the patent claim citing Section 3(d) of India&#039;s patent act, which disallows patents on new or tweaked versions of known or old drug molecules. Many health activists regard this clause as a safeguard.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Gilead has the right to move an appeal with the patent authority or approach an Indian court.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 16 January, 2015, http://www.telegraphindia.com/1150116/jsp/nation/story_8708.jsp#.VLiwoHvxyBE&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;fillip-to-cheaper-hepatitis-c-drug-gs-mudur-4675073&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4675073,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 27028
$metaTitle = &#039;LATEST NEWS UPDATES | Fillip to cheaper hepatitis C drug -GS Mudur&#039;
$metaKeywords = &#039;Intellectual Property Rights,IPRs,patent,patents,generic medicine,generic medicines,Hepatitis C&#039;
$metaDesc = &#039;
-The Telegraph


New Delhi: India&#039;s patent regulating agency today rejected a US company&#039;s patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.


The Indian Patents Controller has denied...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;New Delhi: &lt;/em&gt;India&#039;s patent regulating agency today rejected a US company&#039;s patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900 (Rs 55,600) for a 12-week course of treatment.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The decision will allow generic drug makers to manufacture their own low-cost versions of the medicine. A research study by scientists at the University of Liverpool, published last year, had calculated that the medicine could be produced for only $101 (Rs 6,240) for the 12-week course of treatment.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;This drug makes hepatitis C treatment more effective. We&#039;re hoping this decision opens the floodgates for more open competition that could rapidly lower the price,&amp;quot; said Manica Balasegaram, executive director with the Medecins Sans Frontieres&#039; (MSF) Access Campaign, a humanitarian initiative to expand access to drugs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sofosbuvir is available in the US for $84,000 (Rs 51.9 lakh) for a course of treatment but Gilead - while awaiting a decision from India&#039;s patent office - had last September announced that it would sell the drug in India at $900.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It had also signed pacts with seven Indian drug companies, allowing them to sell generic versions of the drug at even lower prices. But patients&#039; rights groups believe the drug would remain out of reach of most Indian patients even at those lowered prices.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The MSF Access Campaign plans to expand treatment for hepatitis C in India and eight other developing countries. It has been hoping for inexpensive versions of the medicine that it expects will remain the &amp;quot;backbone of (the) hepatitis C treatment regimen in the coming years&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Currently, treatment for the hepatitis C viral infection involves an injectable product called pegylated interferon with an anti-viral drug called ribavarin.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;But, an MSF official said, the success rate of the pegylated interferon regimen in eliminating the infection is about 70 per cent, while it is over 90 per cent with sofosbuvir.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We know from various manufacturers in India that they could produce this drug in future for as little as $101 for a three-month course of treatment,&amp;quot; said Andrew Hill, a senior research fellow at Liverpool University in the UK.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Hill and his colleagues had last year published a study in the journal Clinical Infectious Diseases in which they had estimated that the manufacturing costs of several &amp;quot;direct-acting&amp;quot; anti-viral drugs, sofosbuvir among them, could range between $100 and $250 for a 12-week treatment course.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The patent examiners denied the patent claim citing Section 3(d) of India&#039;s patent act, which disallows patents on new or tweaked versions of known or old drug molecules. Many health activists regard this clause as a safeguard.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Gilead has the right to move an appeal with the patent authority or approach an Indian court.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/fillip-to-cheaper-hepatitis-c-drug-gs-mudur-4675073.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Fillip to cheaper hepatitis C drug -GS Mudur | Im4change.org</title>
    <meta name="description" content="
-The Telegraph


New Delhi: India's patent regulating agency today rejected a US company's patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.


The Indian Patents Controller has denied..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Fillip to cheaper hepatitis C drug -GS Mudur</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph</div><p align="justify"><em>New Delhi: </em>India's patent regulating agency today rejected a US company's patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.</p><p align="justify">The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900 (Rs 55,600) for a 12-week course of treatment.</p><p align="justify">The decision will allow generic drug makers to manufacture their own low-cost versions of the medicine. A research study by scientists at the University of Liverpool, published last year, had calculated that the medicine could be produced for only $101 (Rs 6,240) for the 12-week course of treatment.</p><p align="justify">&quot;This drug makes hepatitis C treatment more effective. We're hoping this decision opens the floodgates for more open competition that could rapidly lower the price,&quot; said Manica Balasegaram, executive director with the Medecins Sans Frontieres' (MSF) Access Campaign, a humanitarian initiative to expand access to drugs.</p><p align="justify">Sofosbuvir is available in the US for $84,000 (Rs 51.9 lakh) for a course of treatment but Gilead - while awaiting a decision from India's patent office - had last September announced that it would sell the drug in India at $900.</p><p align="justify">It had also signed pacts with seven Indian drug companies, allowing them to sell generic versions of the drug at even lower prices. But patients' rights groups believe the drug would remain out of reach of most Indian patients even at those lowered prices.</p><p align="justify">The MSF Access Campaign plans to expand treatment for hepatitis C in India and eight other developing countries. It has been hoping for inexpensive versions of the medicine that it expects will remain the &quot;backbone of (the) hepatitis C treatment regimen in the coming years&quot;.</p><p align="justify">Currently, treatment for the hepatitis C viral infection involves an injectable product called pegylated interferon with an anti-viral drug called ribavarin.</p><p align="justify">But, an MSF official said, the success rate of the pegylated interferon regimen in eliminating the infection is about 70 per cent, while it is over 90 per cent with sofosbuvir.</p><p align="justify">&quot;We know from various manufacturers in India that they could produce this drug in future for as little as $101 for a three-month course of treatment,&quot; said Andrew Hill, a senior research fellow at Liverpool University in the UK.</p><p align="justify">Hill and his colleagues had last year published a study in the journal Clinical Infectious Diseases in which they had estimated that the manufacturing costs of several &quot;direct-acting&quot; anti-viral drugs, sofosbuvir among them, could range between $100 and $250 for a 12-week treatment course.</p><p align="justify">The patent examiners denied the patent claim citing Section 3(d) of India's patent act, which disallows patents on new or tweaked versions of known or old drug molecules. Many health activists regard this clause as a safeguard.</p><p align="justify">Gilead has the right to move an appeal with the patent authority or approach an Indian court.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68030c5f75e61-trace').style.display = (document.getElementById('cakeErr68030c5f75e61-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr68030c5f75e61-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68030c5f75e61-code').style.display = (document.getElementById('cakeErr68030c5f75e61-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr68030c5f75e61-context').style.display = (document.getElementById('cakeErr68030c5f75e61-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr68030c5f75e61-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr68030c5f75e61-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 27028,
		&#039;title&#039; =&gt; &#039;Fillip to cheaper hepatitis C drug -GS Mudur&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;India&#039;s patent regulating agency today rejected a US company&#039;s patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900 (Rs 55,600) for a 12-week course of treatment.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The decision will allow generic drug makers to manufacture their own low-cost versions of the medicine. A research study by scientists at the University of Liverpool, published last year, had calculated that the medicine could be produced for only $101 (Rs 6,240) for the 12-week course of treatment.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;This drug makes hepatitis C treatment more effective. We&#039;re hoping this decision opens the floodgates for more open competition that could rapidly lower the price,&amp;quot; said Manica Balasegaram, executive director with the Medecins Sans Frontieres&#039; (MSF) Access Campaign, a humanitarian initiative to expand access to drugs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sofosbuvir is available in the US for $84,000 (Rs 51.9 lakh) for a course of treatment but Gilead - while awaiting a decision from India&#039;s patent office - had last September announced that it would sell the drug in India at $900.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It had also signed pacts with seven Indian drug companies, allowing them to sell generic versions of the drug at even lower prices. But patients&#039; rights groups believe the drug would remain out of reach of most Indian patients even at those lowered prices.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The MSF Access Campaign plans to expand treatment for hepatitis C in India and eight other developing countries. It has been hoping for inexpensive versions of the medicine that it expects will remain the &amp;quot;backbone of (the) hepatitis C treatment regimen in the coming years&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Currently, treatment for the hepatitis C viral infection involves an injectable product called pegylated interferon with an anti-viral drug called ribavarin.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
But, an MSF official said, the success rate of the pegylated interferon regimen in eliminating the infection is about 70 per cent, while it is over 90 per cent with sofosbuvir.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We know from various manufacturers in India that they could produce this drug in future for as little as $101 for a three-month course of treatment,&amp;quot; said Andrew Hill, a senior research fellow at Liverpool University in the UK.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Hill and his colleagues had last year published a study in the journal Clinical Infectious Diseases in which they had estimated that the manufacturing costs of several &amp;quot;direct-acting&amp;quot; anti-viral drugs, sofosbuvir among them, could range between $100 and $250 for a 12-week treatment course.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The patent examiners denied the patent claim citing Section 3(d) of India&#039;s patent act, which disallows patents on new or tweaked versions of known or old drug molecules. Many health activists regard this clause as a safeguard.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Gilead has the right to move an appeal with the patent authority or approach an Indian court.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 16 January, 2015, http://www.telegraphindia.com/1150116/jsp/nation/story_8708.jsp#.VLiwoHvxyBE&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;fillip-to-cheaper-hepatitis-c-drug-gs-mudur-4675073&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4675073,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 27028,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Fillip to cheaper hepatitis C drug -GS Mudur&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Intellectual Property Rights,IPRs,patent,patents,generic medicine,generic medicines,Hepatitis C&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph


New Delhi: India&#039;s patent regulating agency today rejected a US company&#039;s patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.


The Indian Patents Controller has denied...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;New Delhi: &lt;/em&gt;India&#039;s patent regulating agency today rejected a US company&#039;s patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900 (Rs 55,600) for a 12-week course of treatment.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The decision will allow generic drug makers to manufacture their own low-cost versions of the medicine. A research study by scientists at the University of Liverpool, published last year, had calculated that the medicine could be produced for only $101 (Rs 6,240) for the 12-week course of treatment.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;This drug makes hepatitis C treatment more effective. We&#039;re hoping this decision opens the floodgates for more open competition that could rapidly lower the price,&amp;quot; said Manica Balasegaram, executive director with the Medecins Sans Frontieres&#039; (MSF) Access Campaign, a humanitarian initiative to expand access to drugs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sofosbuvir is available in the US for $84,000 (Rs 51.9 lakh) for a course of treatment but Gilead - while awaiting a decision from India&#039;s patent office - had last September announced that it would sell the drug in India at $900.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It had also signed pacts with seven Indian drug companies, allowing them to sell generic versions of the drug at even lower prices. But patients&#039; rights groups believe the drug would remain out of reach of most Indian patients even at those lowered prices.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The MSF Access Campaign plans to expand treatment for hepatitis C in India and eight other developing countries. It has been hoping for inexpensive versions of the medicine that it expects will remain the &amp;quot;backbone of (the) hepatitis C treatment regimen in the coming years&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Currently, treatment for the hepatitis C viral infection involves an injectable product called pegylated interferon with an anti-viral drug called ribavarin.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;But, an MSF official said, the success rate of the pegylated interferon regimen in eliminating the infection is about 70 per cent, while it is over 90 per cent with sofosbuvir.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We know from various manufacturers in India that they could produce this drug in future for as little as $101 for a three-month course of treatment,&amp;quot; said Andrew Hill, a senior research fellow at Liverpool University in the UK.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Hill and his colleagues had last year published a study in the journal Clinical Infectious Diseases in which they had estimated that the manufacturing costs of several &amp;quot;direct-acting&amp;quot; anti-viral drugs, sofosbuvir among them, could range between $100 and $250 for a 12-week treatment course.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The patent examiners denied the patent claim citing Section 3(d) of India&#039;s patent act, which disallows patents on new or tweaked versions of known or old drug molecules. Many health activists regard this clause as a safeguard.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Gilead has the right to move an appeal with the patent authority or approach an Indian court.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 27028,
	&#039;title&#039; =&gt; &#039;Fillip to cheaper hepatitis C drug -GS Mudur&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;India&#039;s patent regulating agency today rejected a US company&#039;s patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900 (Rs 55,600) for a 12-week course of treatment.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The decision will allow generic drug makers to manufacture their own low-cost versions of the medicine. A research study by scientists at the University of Liverpool, published last year, had calculated that the medicine could be produced for only $101 (Rs 6,240) for the 12-week course of treatment.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;This drug makes hepatitis C treatment more effective. We&#039;re hoping this decision opens the floodgates for more open competition that could rapidly lower the price,&amp;quot; said Manica Balasegaram, executive director with the Medecins Sans Frontieres&#039; (MSF) Access Campaign, a humanitarian initiative to expand access to drugs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sofosbuvir is available in the US for $84,000 (Rs 51.9 lakh) for a course of treatment but Gilead - while awaiting a decision from India&#039;s patent office - had last September announced that it would sell the drug in India at $900.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It had also signed pacts with seven Indian drug companies, allowing them to sell generic versions of the drug at even lower prices. But patients&#039; rights groups believe the drug would remain out of reach of most Indian patients even at those lowered prices.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The MSF Access Campaign plans to expand treatment for hepatitis C in India and eight other developing countries. It has been hoping for inexpensive versions of the medicine that it expects will remain the &amp;quot;backbone of (the) hepatitis C treatment regimen in the coming years&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Currently, treatment for the hepatitis C viral infection involves an injectable product called pegylated interferon with an anti-viral drug called ribavarin.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
But, an MSF official said, the success rate of the pegylated interferon regimen in eliminating the infection is about 70 per cent, while it is over 90 per cent with sofosbuvir.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We know from various manufacturers in India that they could produce this drug in future for as little as $101 for a three-month course of treatment,&amp;quot; said Andrew Hill, a senior research fellow at Liverpool University in the UK.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Hill and his colleagues had last year published a study in the journal Clinical Infectious Diseases in which they had estimated that the manufacturing costs of several &amp;quot;direct-acting&amp;quot; anti-viral drugs, sofosbuvir among them, could range between $100 and $250 for a 12-week treatment course.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The patent examiners denied the patent claim citing Section 3(d) of India&#039;s patent act, which disallows patents on new or tweaked versions of known or old drug molecules. Many health activists regard this clause as a safeguard.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Gilead has the right to move an appeal with the patent authority or approach an Indian court.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 16 January, 2015, http://www.telegraphindia.com/1150116/jsp/nation/story_8708.jsp#.VLiwoHvxyBE&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;fillip-to-cheaper-hepatitis-c-drug-gs-mudur-4675073&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4675073,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 27028
$metaTitle = &#039;LATEST NEWS UPDATES | Fillip to cheaper hepatitis C drug -GS Mudur&#039;
$metaKeywords = &#039;Intellectual Property Rights,IPRs,patent,patents,generic medicine,generic medicines,Hepatitis C&#039;
$metaDesc = &#039;
-The Telegraph


New Delhi: India&#039;s patent regulating agency today rejected a US company&#039;s patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.


The Indian Patents Controller has denied...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;New Delhi: &lt;/em&gt;India&#039;s patent regulating agency today rejected a US company&#039;s patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900 (Rs 55,600) for a 12-week course of treatment.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The decision will allow generic drug makers to manufacture their own low-cost versions of the medicine. A research study by scientists at the University of Liverpool, published last year, had calculated that the medicine could be produced for only $101 (Rs 6,240) for the 12-week course of treatment.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;This drug makes hepatitis C treatment more effective. We&#039;re hoping this decision opens the floodgates for more open competition that could rapidly lower the price,&amp;quot; said Manica Balasegaram, executive director with the Medecins Sans Frontieres&#039; (MSF) Access Campaign, a humanitarian initiative to expand access to drugs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sofosbuvir is available in the US for $84,000 (Rs 51.9 lakh) for a course of treatment but Gilead - while awaiting a decision from India&#039;s patent office - had last September announced that it would sell the drug in India at $900.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It had also signed pacts with seven Indian drug companies, allowing them to sell generic versions of the drug at even lower prices. But patients&#039; rights groups believe the drug would remain out of reach of most Indian patients even at those lowered prices.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The MSF Access Campaign plans to expand treatment for hepatitis C in India and eight other developing countries. It has been hoping for inexpensive versions of the medicine that it expects will remain the &amp;quot;backbone of (the) hepatitis C treatment regimen in the coming years&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Currently, treatment for the hepatitis C viral infection involves an injectable product called pegylated interferon with an anti-viral drug called ribavarin.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;But, an MSF official said, the success rate of the pegylated interferon regimen in eliminating the infection is about 70 per cent, while it is over 90 per cent with sofosbuvir.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We know from various manufacturers in India that they could produce this drug in future for as little as $101 for a three-month course of treatment,&amp;quot; said Andrew Hill, a senior research fellow at Liverpool University in the UK.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Hill and his colleagues had last year published a study in the journal Clinical Infectious Diseases in which they had estimated that the manufacturing costs of several &amp;quot;direct-acting&amp;quot; anti-viral drugs, sofosbuvir among them, could range between $100 and $250 for a 12-week treatment course.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The patent examiners denied the patent claim citing Section 3(d) of India&#039;s patent act, which disallows patents on new or tweaked versions of known or old drug molecules. Many health activists regard this clause as a safeguard.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Gilead has the right to move an appeal with the patent authority or approach an Indian court.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/fillip-to-cheaper-hepatitis-c-drug-gs-mudur-4675073.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Fillip to cheaper hepatitis C drug -GS Mudur | Im4change.org</title>
    <meta name="description" content="
-The Telegraph


New Delhi: India's patent regulating agency today rejected a US company's patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.


The Indian Patents Controller has denied..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Fillip to cheaper hepatitis C drug -GS Mudur</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph</div><p align="justify"><em>New Delhi: </em>India's patent regulating agency today rejected a US company's patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.</p><p align="justify">The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900 (Rs 55,600) for a 12-week course of treatment.</p><p align="justify">The decision will allow generic drug makers to manufacture their own low-cost versions of the medicine. A research study by scientists at the University of Liverpool, published last year, had calculated that the medicine could be produced for only $101 (Rs 6,240) for the 12-week course of treatment.</p><p align="justify">&quot;This drug makes hepatitis C treatment more effective. We're hoping this decision opens the floodgates for more open competition that could rapidly lower the price,&quot; said Manica Balasegaram, executive director with the Medecins Sans Frontieres' (MSF) Access Campaign, a humanitarian initiative to expand access to drugs.</p><p align="justify">Sofosbuvir is available in the US for $84,000 (Rs 51.9 lakh) for a course of treatment but Gilead - while awaiting a decision from India's patent office - had last September announced that it would sell the drug in India at $900.</p><p align="justify">It had also signed pacts with seven Indian drug companies, allowing them to sell generic versions of the drug at even lower prices. But patients' rights groups believe the drug would remain out of reach of most Indian patients even at those lowered prices.</p><p align="justify">The MSF Access Campaign plans to expand treatment for hepatitis C in India and eight other developing countries. It has been hoping for inexpensive versions of the medicine that it expects will remain the &quot;backbone of (the) hepatitis C treatment regimen in the coming years&quot;.</p><p align="justify">Currently, treatment for the hepatitis C viral infection involves an injectable product called pegylated interferon with an anti-viral drug called ribavarin.</p><p align="justify">But, an MSF official said, the success rate of the pegylated interferon regimen in eliminating the infection is about 70 per cent, while it is over 90 per cent with sofosbuvir.</p><p align="justify">&quot;We know from various manufacturers in India that they could produce this drug in future for as little as $101 for a three-month course of treatment,&quot; said Andrew Hill, a senior research fellow at Liverpool University in the UK.</p><p align="justify">Hill and his colleagues had last year published a study in the journal Clinical Infectious Diseases in which they had estimated that the manufacturing costs of several &quot;direct-acting&quot; anti-viral drugs, sofosbuvir among them, could range between $100 and $250 for a 12-week treatment course.</p><p align="justify">The patent examiners denied the patent claim citing Section 3(d) of India's patent act, which disallows patents on new or tweaked versions of known or old drug molecules. Many health activists regard this clause as a safeguard.</p><p align="justify">Gilead has the right to move an appeal with the patent authority or approach an Indian court.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68030c5f75e61-trace').style.display = (document.getElementById('cakeErr68030c5f75e61-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr68030c5f75e61-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68030c5f75e61-code').style.display = (document.getElementById('cakeErr68030c5f75e61-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr68030c5f75e61-context').style.display = (document.getElementById('cakeErr68030c5f75e61-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr68030c5f75e61-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr68030c5f75e61-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 27028,
		&#039;title&#039; =&gt; &#039;Fillip to cheaper hepatitis C drug -GS Mudur&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;India&#039;s patent regulating agency today rejected a US company&#039;s patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900 (Rs 55,600) for a 12-week course of treatment.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The decision will allow generic drug makers to manufacture their own low-cost versions of the medicine. A research study by scientists at the University of Liverpool, published last year, had calculated that the medicine could be produced for only $101 (Rs 6,240) for the 12-week course of treatment.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;This drug makes hepatitis C treatment more effective. We&#039;re hoping this decision opens the floodgates for more open competition that could rapidly lower the price,&amp;quot; said Manica Balasegaram, executive director with the Medecins Sans Frontieres&#039; (MSF) Access Campaign, a humanitarian initiative to expand access to drugs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sofosbuvir is available in the US for $84,000 (Rs 51.9 lakh) for a course of treatment but Gilead - while awaiting a decision from India&#039;s patent office - had last September announced that it would sell the drug in India at $900.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It had also signed pacts with seven Indian drug companies, allowing them to sell generic versions of the drug at even lower prices. But patients&#039; rights groups believe the drug would remain out of reach of most Indian patients even at those lowered prices.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The MSF Access Campaign plans to expand treatment for hepatitis C in India and eight other developing countries. It has been hoping for inexpensive versions of the medicine that it expects will remain the &amp;quot;backbone of (the) hepatitis C treatment regimen in the coming years&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Currently, treatment for the hepatitis C viral infection involves an injectable product called pegylated interferon with an anti-viral drug called ribavarin.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
But, an MSF official said, the success rate of the pegylated interferon regimen in eliminating the infection is about 70 per cent, while it is over 90 per cent with sofosbuvir.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We know from various manufacturers in India that they could produce this drug in future for as little as $101 for a three-month course of treatment,&amp;quot; said Andrew Hill, a senior research fellow at Liverpool University in the UK.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Hill and his colleagues had last year published a study in the journal Clinical Infectious Diseases in which they had estimated that the manufacturing costs of several &amp;quot;direct-acting&amp;quot; anti-viral drugs, sofosbuvir among them, could range between $100 and $250 for a 12-week treatment course.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The patent examiners denied the patent claim citing Section 3(d) of India&#039;s patent act, which disallows patents on new or tweaked versions of known or old drug molecules. Many health activists regard this clause as a safeguard.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Gilead has the right to move an appeal with the patent authority or approach an Indian court.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 16 January, 2015, http://www.telegraphindia.com/1150116/jsp/nation/story_8708.jsp#.VLiwoHvxyBE&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;fillip-to-cheaper-hepatitis-c-drug-gs-mudur-4675073&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4675073,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 27028,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Fillip to cheaper hepatitis C drug -GS Mudur&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Intellectual Property Rights,IPRs,patent,patents,generic medicine,generic medicines,Hepatitis C&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph


New Delhi: India&#039;s patent regulating agency today rejected a US company&#039;s patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.


The Indian Patents Controller has denied...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;New Delhi: &lt;/em&gt;India&#039;s patent regulating agency today rejected a US company&#039;s patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900 (Rs 55,600) for a 12-week course of treatment.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The decision will allow generic drug makers to manufacture their own low-cost versions of the medicine. A research study by scientists at the University of Liverpool, published last year, had calculated that the medicine could be produced for only $101 (Rs 6,240) for the 12-week course of treatment.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;This drug makes hepatitis C treatment more effective. We&#039;re hoping this decision opens the floodgates for more open competition that could rapidly lower the price,&amp;quot; said Manica Balasegaram, executive director with the Medecins Sans Frontieres&#039; (MSF) Access Campaign, a humanitarian initiative to expand access to drugs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sofosbuvir is available in the US for $84,000 (Rs 51.9 lakh) for a course of treatment but Gilead - while awaiting a decision from India&#039;s patent office - had last September announced that it would sell the drug in India at $900.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It had also signed pacts with seven Indian drug companies, allowing them to sell generic versions of the drug at even lower prices. But patients&#039; rights groups believe the drug would remain out of reach of most Indian patients even at those lowered prices.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The MSF Access Campaign plans to expand treatment for hepatitis C in India and eight other developing countries. It has been hoping for inexpensive versions of the medicine that it expects will remain the &amp;quot;backbone of (the) hepatitis C treatment regimen in the coming years&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Currently, treatment for the hepatitis C viral infection involves an injectable product called pegylated interferon with an anti-viral drug called ribavarin.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;But, an MSF official said, the success rate of the pegylated interferon regimen in eliminating the infection is about 70 per cent, while it is over 90 per cent with sofosbuvir.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We know from various manufacturers in India that they could produce this drug in future for as little as $101 for a three-month course of treatment,&amp;quot; said Andrew Hill, a senior research fellow at Liverpool University in the UK.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Hill and his colleagues had last year published a study in the journal Clinical Infectious Diseases in which they had estimated that the manufacturing costs of several &amp;quot;direct-acting&amp;quot; anti-viral drugs, sofosbuvir among them, could range between $100 and $250 for a 12-week treatment course.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The patent examiners denied the patent claim citing Section 3(d) of India&#039;s patent act, which disallows patents on new or tweaked versions of known or old drug molecules. Many health activists regard this clause as a safeguard.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Gilead has the right to move an appeal with the patent authority or approach an Indian court.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 27028,
	&#039;title&#039; =&gt; &#039;Fillip to cheaper hepatitis C drug -GS Mudur&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;India&#039;s patent regulating agency today rejected a US company&#039;s patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900 (Rs 55,600) for a 12-week course of treatment.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The decision will allow generic drug makers to manufacture their own low-cost versions of the medicine. A research study by scientists at the University of Liverpool, published last year, had calculated that the medicine could be produced for only $101 (Rs 6,240) for the 12-week course of treatment.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;This drug makes hepatitis C treatment more effective. We&#039;re hoping this decision opens the floodgates for more open competition that could rapidly lower the price,&amp;quot; said Manica Balasegaram, executive director with the Medecins Sans Frontieres&#039; (MSF) Access Campaign, a humanitarian initiative to expand access to drugs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sofosbuvir is available in the US for $84,000 (Rs 51.9 lakh) for a course of treatment but Gilead - while awaiting a decision from India&#039;s patent office - had last September announced that it would sell the drug in India at $900.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It had also signed pacts with seven Indian drug companies, allowing them to sell generic versions of the drug at even lower prices. But patients&#039; rights groups believe the drug would remain out of reach of most Indian patients even at those lowered prices.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The MSF Access Campaign plans to expand treatment for hepatitis C in India and eight other developing countries. It has been hoping for inexpensive versions of the medicine that it expects will remain the &amp;quot;backbone of (the) hepatitis C treatment regimen in the coming years&amp;quot;.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Currently, treatment for the hepatitis C viral infection involves an injectable product called pegylated interferon with an anti-viral drug called ribavarin.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
But, an MSF official said, the success rate of the pegylated interferon regimen in eliminating the infection is about 70 per cent, while it is over 90 per cent with sofosbuvir.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We know from various manufacturers in India that they could produce this drug in future for as little as $101 for a three-month course of treatment,&amp;quot; said Andrew Hill, a senior research fellow at Liverpool University in the UK.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Hill and his colleagues had last year published a study in the journal Clinical Infectious Diseases in which they had estimated that the manufacturing costs of several &amp;quot;direct-acting&amp;quot; anti-viral drugs, sofosbuvir among them, could range between $100 and $250 for a 12-week treatment course.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The patent examiners denied the patent claim citing Section 3(d) of India&#039;s patent act, which disallows patents on new or tweaked versions of known or old drug molecules. Many health activists regard this clause as a safeguard.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Gilead has the right to move an appeal with the patent authority or approach an Indian court.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 16 January, 2015, http://www.telegraphindia.com/1150116/jsp/nation/story_8708.jsp#.VLiwoHvxyBE&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;fillip-to-cheaper-hepatitis-c-drug-gs-mudur-4675073&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4675073,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 27028
$metaTitle = &#039;LATEST NEWS UPDATES | Fillip to cheaper hepatitis C drug -GS Mudur&#039;
$metaKeywords = &#039;Intellectual Property Rights,IPRs,patent,patents,generic medicine,generic medicines,Hepatitis C&#039;
$metaDesc = &#039;
-The Telegraph


New Delhi: India&#039;s patent regulating agency today rejected a US company&#039;s patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.


The Indian Patents Controller has denied...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;New Delhi: &lt;/em&gt;India&#039;s patent regulating agency today rejected a US company&#039;s patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900 (Rs 55,600) for a 12-week course of treatment.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The decision will allow generic drug makers to manufacture their own low-cost versions of the medicine. A research study by scientists at the University of Liverpool, published last year, had calculated that the medicine could be produced for only $101 (Rs 6,240) for the 12-week course of treatment.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;This drug makes hepatitis C treatment more effective. We&#039;re hoping this decision opens the floodgates for more open competition that could rapidly lower the price,&amp;quot; said Manica Balasegaram, executive director with the Medecins Sans Frontieres&#039; (MSF) Access Campaign, a humanitarian initiative to expand access to drugs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sofosbuvir is available in the US for $84,000 (Rs 51.9 lakh) for a course of treatment but Gilead - while awaiting a decision from India&#039;s patent office - had last September announced that it would sell the drug in India at $900.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It had also signed pacts with seven Indian drug companies, allowing them to sell generic versions of the drug at even lower prices. But patients&#039; rights groups believe the drug would remain out of reach of most Indian patients even at those lowered prices.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The MSF Access Campaign plans to expand treatment for hepatitis C in India and eight other developing countries. It has been hoping for inexpensive versions of the medicine that it expects will remain the &amp;quot;backbone of (the) hepatitis C treatment regimen in the coming years&amp;quot;.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Currently, treatment for the hepatitis C viral infection involves an injectable product called pegylated interferon with an anti-viral drug called ribavarin.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;But, an MSF official said, the success rate of the pegylated interferon regimen in eliminating the infection is about 70 per cent, while it is over 90 per cent with sofosbuvir.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We know from various manufacturers in India that they could produce this drug in future for as little as $101 for a three-month course of treatment,&amp;quot; said Andrew Hill, a senior research fellow at Liverpool University in the UK.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Hill and his colleagues had last year published a study in the journal Clinical Infectious Diseases in which they had estimated that the manufacturing costs of several &amp;quot;direct-acting&amp;quot; anti-viral drugs, sofosbuvir among them, could range between $100 and $250 for a 12-week treatment course.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The patent examiners denied the patent claim citing Section 3(d) of India&#039;s patent act, which disallows patents on new or tweaked versions of known or old drug molecules. Many health activists regard this clause as a safeguard.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Gilead has the right to move an appeal with the patent authority or approach an Indian court.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/fillip-to-cheaper-hepatitis-c-drug-gs-mudur-4675073.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Fillip to cheaper hepatitis C drug -GS Mudur | Im4change.org</title>
    <meta name="description" content="
-The Telegraph


New Delhi: India's patent regulating agency today rejected a US company's patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.


The Indian Patents Controller has denied..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Fillip to cheaper hepatitis C drug -GS Mudur</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph</div><p align="justify"><em>New Delhi: </em>India's patent regulating agency today rejected a US company's patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.</p><p align="justify">The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900 (Rs 55,600) for a 12-week course of treatment.</p><p align="justify">The decision will allow generic drug makers to manufacture their own low-cost versions of the medicine. A research study by scientists at the University of Liverpool, published last year, had calculated that the medicine could be produced for only $101 (Rs 6,240) for the 12-week course of treatment.</p><p align="justify">&quot;This drug makes hepatitis C treatment more effective. We're hoping this decision opens the floodgates for more open competition that could rapidly lower the price,&quot; said Manica Balasegaram, executive director with the Medecins Sans Frontieres' (MSF) Access Campaign, a humanitarian initiative to expand access to drugs.</p><p align="justify">Sofosbuvir is available in the US for $84,000 (Rs 51.9 lakh) for a course of treatment but Gilead - while awaiting a decision from India's patent office - had last September announced that it would sell the drug in India at $900.</p><p align="justify">It had also signed pacts with seven Indian drug companies, allowing them to sell generic versions of the drug at even lower prices. But patients' rights groups believe the drug would remain out of reach of most Indian patients even at those lowered prices.</p><p align="justify">The MSF Access Campaign plans to expand treatment for hepatitis C in India and eight other developing countries. It has been hoping for inexpensive versions of the medicine that it expects will remain the &quot;backbone of (the) hepatitis C treatment regimen in the coming years&quot;.</p><p align="justify">Currently, treatment for the hepatitis C viral infection involves an injectable product called pegylated interferon with an anti-viral drug called ribavarin.</p><p align="justify">But, an MSF official said, the success rate of the pegylated interferon regimen in eliminating the infection is about 70 per cent, while it is over 90 per cent with sofosbuvir.</p><p align="justify">&quot;We know from various manufacturers in India that they could produce this drug in future for as little as $101 for a three-month course of treatment,&quot; said Andrew Hill, a senior research fellow at Liverpool University in the UK.</p><p align="justify">Hill and his colleagues had last year published a study in the journal Clinical Infectious Diseases in which they had estimated that the manufacturing costs of several &quot;direct-acting&quot; anti-viral drugs, sofosbuvir among them, could range between $100 and $250 for a 12-week treatment course.</p><p align="justify">The patent examiners denied the patent claim citing Section 3(d) of India's patent act, which disallows patents on new or tweaked versions of known or old drug molecules. Many health activists regard this clause as a safeguard.</p><p align="justify">Gilead has the right to move an appeal with the patent authority or approach an Indian court.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 27028,
		'title' => 'Fillip to cheaper hepatitis C drug -GS Mudur',
		'subheading' => '',
		'description' => '<div align="justify">
-The Telegraph
</div>
<p align="justify">
<em>New Delhi: </em>India's patent regulating agency today rejected a US company's patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.
</p>
<p align="justify">
The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900 (Rs 55,600) for a 12-week course of treatment.
</p>
<p align="justify">
The decision will allow generic drug makers to manufacture their own low-cost versions of the medicine. A research study by scientists at the University of Liverpool, published last year, had calculated that the medicine could be produced for only $101 (Rs 6,240) for the 12-week course of treatment.
</p>
<p align="justify">
&quot;This drug makes hepatitis C treatment more effective. We're hoping this decision opens the floodgates for more open competition that could rapidly lower the price,&quot; said Manica Balasegaram, executive director with the Medecins Sans Frontieres' (MSF) Access Campaign, a humanitarian initiative to expand access to drugs.
</p>
<p align="justify">
Sofosbuvir is available in the US for $84,000 (Rs 51.9 lakh) for a course of treatment but Gilead - while awaiting a decision from India's patent office - had last September announced that it would sell the drug in India at $900.
</p>
<p align="justify">
It had also signed pacts with seven Indian drug companies, allowing them to sell generic versions of the drug at even lower prices. But patients' rights groups believe the drug would remain out of reach of most Indian patients even at those lowered prices.
</p>
<p align="justify">
The MSF Access Campaign plans to expand treatment for hepatitis C in India and eight other developing countries. It has been hoping for inexpensive versions of the medicine that it expects will remain the &quot;backbone of (the) hepatitis C treatment regimen in the coming years&quot;.
</p>
<p align="justify">
Currently, treatment for the hepatitis C viral infection involves an injectable product called pegylated interferon with an anti-viral drug called ribavarin.
</p>
<p align="justify">
But, an MSF official said, the success rate of the pegylated interferon regimen in eliminating the infection is about 70 per cent, while it is over 90 per cent with sofosbuvir.
</p>
<p align="justify">
&quot;We know from various manufacturers in India that they could produce this drug in future for as little as $101 for a three-month course of treatment,&quot; said Andrew Hill, a senior research fellow at Liverpool University in the UK.
</p>
<p align="justify">
Hill and his colleagues had last year published a study in the journal Clinical Infectious Diseases in which they had estimated that the manufacturing costs of several &quot;direct-acting&quot; anti-viral drugs, sofosbuvir among them, could range between $100 and $250 for a 12-week treatment course.
</p>
<p align="justify">
The patent examiners denied the patent claim citing Section 3(d) of India's patent act, which disallows patents on new or tweaked versions of known or old drug molecules. Many health activists regard this clause as a safeguard.
</p>
<p align="justify">
Gilead has the right to move an appeal with the patent authority or approach an Indian court.
</p>',
		'credit_writer' => 'The Telegraph, 16 January, 2015, http://www.telegraphindia.com/1150116/jsp/nation/story_8708.jsp#.VLiwoHvxyBE',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'fillip-to-cheaper-hepatitis-c-drug-gs-mudur-4675073',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 4675073,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 27028,
	'metaTitle' => 'LATEST NEWS UPDATES | Fillip to cheaper hepatitis C drug -GS Mudur',
	'metaKeywords' => 'Intellectual Property Rights,IPRs,patent,patents,generic medicine,generic medicines,Hepatitis C',
	'metaDesc' => '
-The Telegraph


New Delhi: India's patent regulating agency today rejected a US company's patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.


The Indian Patents Controller has denied...',
	'disp' => '<div align="justify">-The Telegraph</div><p align="justify"><em>New Delhi: </em>India's patent regulating agency today rejected a US company's patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.</p><p align="justify">The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900 (Rs 55,600) for a 12-week course of treatment.</p><p align="justify">The decision will allow generic drug makers to manufacture their own low-cost versions of the medicine. A research study by scientists at the University of Liverpool, published last year, had calculated that the medicine could be produced for only $101 (Rs 6,240) for the 12-week course of treatment.</p><p align="justify">&quot;This drug makes hepatitis C treatment more effective. We're hoping this decision opens the floodgates for more open competition that could rapidly lower the price,&quot; said Manica Balasegaram, executive director with the Medecins Sans Frontieres' (MSF) Access Campaign, a humanitarian initiative to expand access to drugs.</p><p align="justify">Sofosbuvir is available in the US for $84,000 (Rs 51.9 lakh) for a course of treatment but Gilead - while awaiting a decision from India's patent office - had last September announced that it would sell the drug in India at $900.</p><p align="justify">It had also signed pacts with seven Indian drug companies, allowing them to sell generic versions of the drug at even lower prices. But patients' rights groups believe the drug would remain out of reach of most Indian patients even at those lowered prices.</p><p align="justify">The MSF Access Campaign plans to expand treatment for hepatitis C in India and eight other developing countries. It has been hoping for inexpensive versions of the medicine that it expects will remain the &quot;backbone of (the) hepatitis C treatment regimen in the coming years&quot;.</p><p align="justify">Currently, treatment for the hepatitis C viral infection involves an injectable product called pegylated interferon with an anti-viral drug called ribavarin.</p><p align="justify">But, an MSF official said, the success rate of the pegylated interferon regimen in eliminating the infection is about 70 per cent, while it is over 90 per cent with sofosbuvir.</p><p align="justify">&quot;We know from various manufacturers in India that they could produce this drug in future for as little as $101 for a three-month course of treatment,&quot; said Andrew Hill, a senior research fellow at Liverpool University in the UK.</p><p align="justify">Hill and his colleagues had last year published a study in the journal Clinical Infectious Diseases in which they had estimated that the manufacturing costs of several &quot;direct-acting&quot; anti-viral drugs, sofosbuvir among them, could range between $100 and $250 for a 12-week treatment course.</p><p align="justify">The patent examiners denied the patent claim citing Section 3(d) of India's patent act, which disallows patents on new or tweaked versions of known or old drug molecules. Many health activists regard this clause as a safeguard.</p><p align="justify">Gilead has the right to move an appeal with the patent authority or approach an Indian court.</p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 27028,
	'title' => 'Fillip to cheaper hepatitis C drug -GS Mudur',
	'subheading' => '',
	'description' => '<div align="justify">
-The Telegraph
</div>
<p align="justify">
<em>New Delhi: </em>India's patent regulating agency today rejected a US company's patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.
</p>
<p align="justify">
The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900 (Rs 55,600) for a 12-week course of treatment.
</p>
<p align="justify">
The decision will allow generic drug makers to manufacture their own low-cost versions of the medicine. A research study by scientists at the University of Liverpool, published last year, had calculated that the medicine could be produced for only $101 (Rs 6,240) for the 12-week course of treatment.
</p>
<p align="justify">
&quot;This drug makes hepatitis C treatment more effective. We're hoping this decision opens the floodgates for more open competition that could rapidly lower the price,&quot; said Manica Balasegaram, executive director with the Medecins Sans Frontieres' (MSF) Access Campaign, a humanitarian initiative to expand access to drugs.
</p>
<p align="justify">
Sofosbuvir is available in the US for $84,000 (Rs 51.9 lakh) for a course of treatment but Gilead - while awaiting a decision from India's patent office - had last September announced that it would sell the drug in India at $900.
</p>
<p align="justify">
It had also signed pacts with seven Indian drug companies, allowing them to sell generic versions of the drug at even lower prices. But patients' rights groups believe the drug would remain out of reach of most Indian patients even at those lowered prices.
</p>
<p align="justify">
The MSF Access Campaign plans to expand treatment for hepatitis C in India and eight other developing countries. It has been hoping for inexpensive versions of the medicine that it expects will remain the &quot;backbone of (the) hepatitis C treatment regimen in the coming years&quot;.
</p>
<p align="justify">
Currently, treatment for the hepatitis C viral infection involves an injectable product called pegylated interferon with an anti-viral drug called ribavarin.
</p>
<p align="justify">
But, an MSF official said, the success rate of the pegylated interferon regimen in eliminating the infection is about 70 per cent, while it is over 90 per cent with sofosbuvir.
</p>
<p align="justify">
&quot;We know from various manufacturers in India that they could produce this drug in future for as little as $101 for a three-month course of treatment,&quot; said Andrew Hill, a senior research fellow at Liverpool University in the UK.
</p>
<p align="justify">
Hill and his colleagues had last year published a study in the journal Clinical Infectious Diseases in which they had estimated that the manufacturing costs of several &quot;direct-acting&quot; anti-viral drugs, sofosbuvir among them, could range between $100 and $250 for a 12-week treatment course.
</p>
<p align="justify">
The patent examiners denied the patent claim citing Section 3(d) of India's patent act, which disallows patents on new or tweaked versions of known or old drug molecules. Many health activists regard this clause as a safeguard.
</p>
<p align="justify">
Gilead has the right to move an appeal with the patent authority or approach an Indian court.
</p>',
	'credit_writer' => 'The Telegraph, 16 January, 2015, http://www.telegraphindia.com/1150116/jsp/nation/story_8708.jsp#.VLiwoHvxyBE',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'fillip-to-cheaper-hepatitis-c-drug-gs-mudur-4675073',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 4675073,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {},
		(int) 5 => object(Cake\ORM\Entity) {},
		(int) 6 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 27028
$metaTitle = 'LATEST NEWS UPDATES | Fillip to cheaper hepatitis C drug -GS Mudur'
$metaKeywords = 'Intellectual Property Rights,IPRs,patent,patents,generic medicine,generic medicines,Hepatitis C'
$metaDesc = '
-The Telegraph


New Delhi: India's patent regulating agency today rejected a US company's patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.


The Indian Patents Controller has denied...'
$disp = '<div align="justify">-The Telegraph</div><p align="justify"><em>New Delhi: </em>India's patent regulating agency today rejected a US company's patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine.</p><p align="justify">The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900 (Rs 55,600) for a 12-week course of treatment.</p><p align="justify">The decision will allow generic drug makers to manufacture their own low-cost versions of the medicine. A research study by scientists at the University of Liverpool, published last year, had calculated that the medicine could be produced for only $101 (Rs 6,240) for the 12-week course of treatment.</p><p align="justify">&quot;This drug makes hepatitis C treatment more effective. We're hoping this decision opens the floodgates for more open competition that could rapidly lower the price,&quot; said Manica Balasegaram, executive director with the Medecins Sans Frontieres' (MSF) Access Campaign, a humanitarian initiative to expand access to drugs.</p><p align="justify">Sofosbuvir is available in the US for $84,000 (Rs 51.9 lakh) for a course of treatment but Gilead - while awaiting a decision from India's patent office - had last September announced that it would sell the drug in India at $900.</p><p align="justify">It had also signed pacts with seven Indian drug companies, allowing them to sell generic versions of the drug at even lower prices. But patients' rights groups believe the drug would remain out of reach of most Indian patients even at those lowered prices.</p><p align="justify">The MSF Access Campaign plans to expand treatment for hepatitis C in India and eight other developing countries. It has been hoping for inexpensive versions of the medicine that it expects will remain the &quot;backbone of (the) hepatitis C treatment regimen in the coming years&quot;.</p><p align="justify">Currently, treatment for the hepatitis C viral infection involves an injectable product called pegylated interferon with an anti-viral drug called ribavarin.</p><p align="justify">But, an MSF official said, the success rate of the pegylated interferon regimen in eliminating the infection is about 70 per cent, while it is over 90 per cent with sofosbuvir.</p><p align="justify">&quot;We know from various manufacturers in India that they could produce this drug in future for as little as $101 for a three-month course of treatment,&quot; said Andrew Hill, a senior research fellow at Liverpool University in the UK.</p><p align="justify">Hill and his colleagues had last year published a study in the journal Clinical Infectious Diseases in which they had estimated that the manufacturing costs of several &quot;direct-acting&quot; anti-viral drugs, sofosbuvir among them, could range between $100 and $250 for a 12-week treatment course.</p><p align="justify">The patent examiners denied the patent claim citing Section 3(d) of India's patent act, which disallows patents on new or tweaked versions of known or old drug molecules. Many health activists regard this clause as a safeguard.</p><p align="justify">Gilead has the right to move an appeal with the patent authority or approach an Indian court.</p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Fillip to cheaper hepatitis C drug -GS Mudur

-The Telegraph New Delhi: India's patent regulating agency today rejected a US company's patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine. The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900 (Rs 55,600) for a 12-week course of treatment. The decision will allow generic drug makers to manufacture their own low-cost versions of the medicine. A research study by scientists at the University of Liverpool, published last year, had calculated that the medicine could be produced for only $101 (Rs 6,240) for the 12-week course of treatment. "This drug makes hepatitis C treatment more effective. We're hoping this decision opens the floodgates for more open competition that could rapidly lower the price," said Manica Balasegaram, executive director with the Medecins Sans Frontieres' (MSF) Access Campaign, a humanitarian initiative to expand access to drugs. Sofosbuvir is available in the US for $84,000 (Rs 51.9 lakh) for a course of treatment but Gilead - while awaiting a decision from India's patent office - had last September announced that it would sell the drug in India at $900. It had also signed pacts with seven Indian drug companies, allowing them to sell generic versions of the drug at even lower prices. But patients' rights groups believe the drug would remain out of reach of most Indian patients even at those lowered prices. The MSF Access Campaign plans to expand treatment for hepatitis C in India and eight other developing countries. It has been hoping for inexpensive versions of the medicine that it expects will remain the "backbone of (the) hepatitis C treatment regimen in the coming years". Currently, treatment for the hepatitis C viral infection involves an injectable product called pegylated interferon with an anti-viral drug called ribavarin. But, an MSF official said, the success rate of the pegylated interferon regimen in eliminating the infection is about 70 per cent, while it is over 90 per cent with sofosbuvir. "We know from various manufacturers in India that they could produce this drug in future for as little as $101 for a three-month course of treatment," said Andrew Hill, a senior research fellow at Liverpool University in the UK. Hill and his colleagues had last year published a study in the journal Clinical Infectious Diseases in which they had estimated that the manufacturing costs of several "direct-acting" anti-viral drugs, sofosbuvir among them, could range between $100 and $250 for a 12-week treatment course. The patent examiners denied the patent claim citing Section 3(d) of India's patent act, which disallows patents on new or tweaked versions of known or old drug molecules. Many health activists regard this clause as a safeguard. Gilead has the right to move an appeal with the patent authority or approach an Indian court.